Abstract: Despite the availability of effective urate-lowering therapy (ULT) and antiinflammatory drugs for the treatment of gout, there is considerable interest in novel treatment approaches. Patients with gout often have a multitude of comorbidities, leading to concern over drug-drug interactions and medication adverse events. The cherry is a small nutrient-rich fruit that has garnered a great deal of attention in recent years as a nonpharmacologic option for the treatment of a multitude of disease manifestations. Perhaps a quarter of patients with gout try cherries or cherry products to treat their gout, which have antioxidant and anti-inflammatory (IL-6, TNF-α, IL-1β, IL-8, COX-I and -II) properties, hypouricemic effects, and the ability to downregulate NFkB-mediated osteoclastogenesis. Based on these properties, cherries may reduce both the acute and chronic inflammation associated with recurrent gout flares and its chronic destructive arthropathy. In this review, we explore the potential benefits of cherries and cherry products as a nonpharmacologic option for the treatment of gout.
Introduction
Gout is a chronic and often debilitating disease associated with recurrent flares of inflammatory arthritis, manifesting as severe pain and joint dysfunction, which, if untreated, can lead to joint damage and significant morbidity. Once thought of as the disease of kings, gout has a prevalence of 3.9% in the US, affecting 8.3 million adults, 1,2 with a doubling of incidence seen in both men and women over the past 20 years. 3 Several uratelowering therapies (ULTs) successfully decrease the burden of gout; however, they are not without potential risks. Patients with gout often have a multitude of comorbidities, [4] [5] [6] leading to concern over drug-drug interactions and medication adverse events 7 including skin rash, gastrointestinal side effects, infusion reactions, and rare lifethreatening hypersensitivity reactions to certain gout drugs. 8, 9 In fact, patients ranked interaction of gout medication with medications for other medical conditions as one of their biggest concerns when treating gout. 7 Therefore, it is no wonder that many patients afflicted with gout find themselves seeking complementary or alternative therapies.
Qualitative research suggests that approximately a quarter of gout patients use cherry products (cherries, cherry extract, or cherry juice) to treat their gout. 7 An internet-based survey of patients with self-reported, physician-diagnosed gout found that 24% preferred cherry extract as a potential means for chronic ULT. 10 Providers and patients believe that more ULT options are needed, since a proportion of patients with gout cannot be treated with the currently available ULTs due to low medication adherence, contraindications, inefficacy or partial efficacy, or adverse events. 11 Patients also prefer disease self-management strategies such as diet modification, exercise, weight reduction, medication self-management, as well as use of natural therapies as management options for their chronic diseases. 12, 13 This implies that additional treatment options for gout, including complementary medicines such as cherries, are of high interest to patients and possibly to healthcare providers as well.
Cherries
The cherry is a small nutrient-rich fruit garnering a great deal of attention as a nonpharmacologic option for the treatment of a multitude of disease manifestations in recent years. Cherries contain vitamins A, C, E, and phenolics such as anthocyanins 14, 15 (Table 1 ). The recognition of antioxidant and anti-inflammatory properties of cherries has prompted numerous studies examining their benefits in patients with gout, 16 insomnia, 17 muscle endurance and recovery, 18 and potential benefit in cardiovascular disease, 19, 20 diabetes, 20, 21 and cancer. 22 Cherries are typically grouped into two major categories, sweet (Prunus avium) and tart /sour (Prunus cerasus). The most commonly grown cultivar of sweet cherry in the US is the Bing, while the most common for tart cherry is the Montmorency cherry. 14 The stage of ripening, among other things, plays a role in the content of potentially therapeutic compounds found in cherries, with ascorbic acid, total phenolics, antioxidant activity, and total anthocyanins increasing as Table 1 . Nutrients found in sweet raw cherries and mean cyanidin content in cherry products.
Cherry product
Mean cyanidin content ** (mg/100 g edible portion) the fruit ripens. 23 In addition to raw cherries, numerous cherry products including juices, powders, concentrates, and extracts are commercially available. For example, one 8 oz bottle of a tart cherry juice blend is equivalent to 50 cherries. 24 One tablespoon (0.5 oz/~15 ml) of cherry juice concentrate made from fresh cherries is equivalent to 45-60 cherries, 25 with a 30 ml (1 oz) dose of Montmorency tart cherry concentrate equivalent to 90 whole Montmorency cherries. 26 Most tart cherry extracts and powders are available as oral capsules, for which one of the available commercial products contains 480 mg of tart Montmorency cherry powder, roughly equivalent to 16 ounces of tart cherry juice. 27 Anthocyanins, phenolic compounds belonging to the family of flavonoids, are water-soluble pigments found in cherries that possess both antioxidant and anti-inflammatory properties, [28] [29] [30] [31] characteristics attracting increasing interest over their potential health benefits. Cherries contain high amounts of anthocyanins as compared with other fruits. The major anthocyanins found in edible fruits like cherries are cyanidin, pelargonidin, peonidin, delphinidin, petunidin, and malvidin, with cyanidin being the most abundant. 15, 28, 32 The mean cyanidin content of the various cherry products can be seen in Table 1 . The highest anthocyanin concentration in cherries is found in Bing cherries (40% higher content in the skins of Bing cherries, and nearly three times the anthocyanin content in the edible portion compared with Montmorency), with the majority of bioactive substances concentrated in the skins of both. 33 The anthocyanin content of cherries can be affected by processing, with canning leading to 50% transfer of anthocyanins and total phenolics from fruit to syrup, with varying degrees of degradation with frozen storage. 33 
Cherries as antioxidants
Through the process of metabolism in normal cells, toxic reactive oxygen and nitrogen species are produced, leading to oxidative stress that can result in severely compromised cell functioning, direct cell injury, and even cell death. 36 Oxidative stress plays a role in the manifestations of gout, precipitated by the generation of reactive oxygen species (ROS) and pro-inflammatory cytokines. 37 The enzyme xanthine oxidoreductase, responsible for the conversion of hypoxanthine to xanthine to urate in the final process of purine metabolism, also leads to the generation of ROS. 38 Anthocyanins and other phenolics found in cherries have antioxidant properties. 31, 33, [39] [40] [41] [42] Phenolic antioxidants appear to interfere with the oxidation process as free radical terminators, and ultimately decrease the formation of volatile decomposition products. 43 Cherry skins have the highest in antioxidant activity, with Montmorency tart cherry skins carrying the highest in total phenolics and antioxidant activities among the cherries tested. 33 Tart cherry juice concentrate has the highest oxygen radical absorbance capacity (ORAC), followed by dried cherries, frozen cherries, and canned cherries. 39 Two animal models evaluated the effect of anthocyanins on the markers of oxidative stress, showing an increase in total antioxidant capacity and superoxide dismutase in rats with adjuvant-induced arthritis, 29 and lower levels of nitrotyrosine and inducible nitric oxide synthetase in the joints of mice with collageninduced arthritis treated with anthocyanin, when compared with untreated controls. 44 Twenty recreational marathon runners had a significant increase (about 10%) in total antioxidative status after 5 days of tart cherry juice use versus placebo, with lower thiobarbituric acid reactive species, a marker of oxidative stress, 48 h postrace. 45 
Anti-inflammatory effects of cherries and anthocyanins

Cytokine inhibition
Gout is associated with the tissue deposition of urate crystals in the setting of hyperuricemia, with a subsequent crystal-induced inflammatory response. Urate crystals stimulate monocyte and synovial cell production of interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α), 46, 47 as well as chemotactic IL-8. 48 When stimulated by IL-1, IL-6, and IL-23, T-helper 17 (Th17) cells produce pro-inflammatory cytokines including IL-6, IL-17, and TNF-α. 49 Recent work has also shown that urate crystals activate the NACHT, leucinrich repeat and pyrin domains containing protein (NALP3) inflammasome, 50 resulting in the production of IL-1β, whose inhibition has been shown to prevent the pain and inflammation response to urate. 51 Despite positive results from studies of the antiinflammatory effects of both cherries and anthocyanins, the data are limited at best. In a murine 44 Rats with adjuvant-induced arthritis treated with anthocyanins extracted from tart cherries had lower levels of both TNF-α and prostaglandin E2 (PGE 2 ) in the paws. 29 IL-6 production was inhibited by 41-96% in an in vitro study using cluster of differentiation 40 ligand (CD40L)-stimulated vascular endothelial cells treated with anthocyanin metabolites. 19 Vascular cell adhesion molecule-1 (VCAM-1), whose expression during an inflammatory state mediates leukocyte adhesion, 52 was reduced by up to 65% with anthocyanins extracted from tart cherries, 19 indicating that anthocyanins may also play a role in leukocyte migration. Despite evidence of significant anti-inflammatory effects of anthocyanins from in vitro and animal models, there is a lack of studies examining its clinical benefit in humans. A randomized, double-blind, placebo-controlled trial investigating the antiinflammatory effect of 320 mg/day of purified anthocyanin in 150 hypercholesterolemic adults found that patients treated with purified anthocyanin had significantly decreased plasma levels of IL-1β and soluble VCAM-1 compared with placebo controls. 53 Interestingly, no significant changes were seen in levels of TNF-α between the two groups, 53 which may relate to the absence of induced inflammation in this study population when compared with the animal models above.
In studies using cherry products, cherry juice concentrate inhibited IL-1β secretion by 60% and TNF-α by 45% in an in vitro study examining the secretion of ILs in monosodium urate (MSU)-stimulated monocytes. 25 Lower postrace levels of IL-6 (49%) were seen in a small study of 20 recreational marathon runners treated with 16 oz/ day of tart cherry juice when compared with placebo controls. 45 However, the small study size and limited/no generalizability to patients with gout are major limitations, indicating that more studies are needed.
Effect on COX-I and COX-II pathways
Prostaglandins, inflammatory instigators whose production is mediated by cyclooxygenases (COXs), are also produced as a result of crystalinduced inflammation. 54 An in vitro study evaluating the COX inhibitory activity of sweet and sour cherries found that red sweet cherries showed the greatest COX-II inhibitory capacity among those tested, with sweet and tart cherries showing similar COX-I inhibition, as seen in Table 2 below. 30 Positive controls in this study were aspirin, celecoxib, and rofecoxib, with rofecoxib showing similar COX-II inhibition to the cherries tested. 30 Tart cherry juice concentrate showed the greatest COX-I inhibitory activity when compared with frozen, dried, and canned tart cherries, 39 with tart cherry extract associated with inhibition of COX-I and COX-II by 65% and 38%, respectively. 20 Anthocyanins from sweet and tart cherries showed similar COX-I inhibition, with greater COX-II inhibition seen in sweet cherries which compared favorably to NSAID controls using ibuprofen and naproxen. 31 These studies would suggest that both sweet and tart cherries contain the ability to inhibit the COX enzymes, with sweet cherries showing superior COX-II inhibition when compared with tart cherries, nevertheless it is important to note that these are all in vitro studies. In human chondrocytes, the anthocyanin delphinidin was shown to inhibit IL-1β-induced expression of COX-II, known to be increased during inflammatory states, 56 as well as the production of PGE 2 55 indicating that even the less-abundant anthocyanins may play a crucial role in decreasing inflammation.
Impact of anthocyanins on osteoclastogenesis
To understand the impact cherries may have in managing patients with gout, we first need to appreciate the pathophysiology of gout. Osteoclasts are important modulators of bone resorption and erosive damage in gout patients. 57 Patients with severe erosive and tophaceous disease have enhanced osteoclastogenesis. 58 Tartrate-resistant acid phosphatase (TRAP), expressed by osteoclasts, is secreted during bone resorption and has been linked to osteoclast activity. 59 TRAP-positive osteoclasts and multinucleated cells are present around tophi and in osteolytic lesions in gout. 58, 60 Their differentiation is regulated by macrophage colony-stimulating factor (M-CSF) and the interaction between nuclear factor kappa-B (NFκB)/ receptor activator of NFκB (RANK) on osteoclast precursor cells and RANK ligand (RANKL) expressed on or secreted by mature osteoblasts. 57, 61 Higher circulating levels of RANKL and M-CSF, 58 
COX-I inhibition COX-II inhibition
Haseeb et al. 55 In vitro study examining the effects of delphinidin on IL-1β mediated expression of COX-II and production of PGE 2 RANK or TRAP-positive multinucleated cells compared with untreated controls. 44 In vitro studies using the anthocyanin cyanidin showed a dose-dependent inhibitory effect on RANKLinduced osteoclastogenesis, 62 inhibition of RANKL-mediated osteoclast differentiation and formation, decreased total TRAP activity, and downregulated expression of osteoclast differentiation marker genes. 63 Pretreatment with cyanidin-3-glucoside also reduced induction of transcription factors important for osteoclast differentiation, 63 with similar results using the anthocyanin delphinidin, which showed a strong inhibitory effect on NFκB activation in chondrocytes. 64 Cyanidin-3-glucoside enhanced genes related to osteoblast differentiation, suggesting cyanidin may also augment bone formation. 63 This suggested that the use of anthocyanins journals.sagepub.com/home/tab 7 could potentially ameliorate osteoclastogenesis in patients with gout, yet is again difficult to draw accurate conclusions when the available studies are of predominantly in vitro design.
Other bioactive components in cherries
Vitamin C Vitamin C, a water-soluble antioxidant found in cherries, has been studied as a potential treatment for gout. Using data from the Health Professionals Follow-up Study, vitamin C intake over a 20-year period in people with no prior history of gout lowered the risk of incident gout by 17% with vitamin C intake of greater than 500 mg/d, with a 45% lower risk for those taking over 1500 mg/day. 65 A second study from the same cohort evaluated the effect of vitamin C intake on serum urate (SU) in men with a body mass index (BMI) < 30 kg/m² and no history of hypertension. 66 Vitamin C intake of 500 mg/day or higher was associated with ~0.7 mg/dl lower level of SU when compared with subjects taking less than 90 mg/day. 66 This study lacked the information on the use of ULT, though a similar result was obtained when gout patients were excluded. A strength of these studies is that they were well powered given the large sample size, though the cohort of male health professionals would not be generalizable to all men. In comparison with the first two studies, doses of 500 mg/day for 8 weeks did not show significant urate-lowering effects in patients with gout already taking allopurinol, 67 but the short follow up and lower dose might explain the absence of an association. Though vitamin C may have a role in lowering SU levels, possibly via a uricosuric effect, 68 one would need large quantities of cherries to glean an overall benefit from a potentially therapeutic dose of vitamin C. The ascorbic acid concentration of sweet cherries is about 28 mg per 100 g, 23 indicating that > 2 kg of cherry intake would be needed to observe an effect similar to the first study noted above. 65 Quercetin Quercetin, a flavonol and member of the flavonoid family of phenolics, 43 is found in a variety of fruits including cherries. According to the United States Department of Agriculture (USDA) database, sour (tart) cherry powder has the highest quercetin content when compared with other cherry products. 34 Quercetin has been well studied for its antioxidant and anti-inflammatory properties, [69] [70] [71] [72] and may be yet another active compound in cherries with beneficial properties for treating gout. Protection against oxidative DNA damage was observed in a dose-dependent manner in a study using quercetin in vitro, with a significant increase in total antioxidant capacity in eight healthy females treated with quercetinrich fruit juice for 4 weeks. 72 Quercetin inhibited in vitro COX-I and II activity by 52.8% and 42.3%, respectively, 20 reduced COX-II mRNA expression in both unstimulated and IL-1β-stimulated colon cancer cells, 73 and significantly decreased COX-II activity in rats with crystalinduced inflammation. 70 Improved arthritis scores, decreased joint circumference, and significantly decreased levels of TNF-α and IL1-β have also been observed in animal models, 70,71 which compared favorably with 3 mg/kg of indomethacin 70 in rats with crystal-induced inflammation. Quercetin reversibly inhibited the formation of urate and superoxide radicals catalyzed by xanthine oxidase (XO) in a concentration-dependent manner similar to that of allopurinol in vitro, 74 suggesting a dual role in gout. Unfortunately, studies evaluating the effects of quercetin in humans are sparse. In a randomized, double-blinded, placebocontrolled, crossover trial evaluating the use of quercetin on plasma urate in 22 healthy prehyperuricemic males, a significant decrease in plasma urate of 8% with daily supplementation for 4 weeks was noted, with a greater urate-lowering effect in patients with higher urate levels when compared with untreated controls. 75 Studies using quercetin can be seen in Table 3 below.
Clinical evidence for cherries in gout: effect on gout flares
In a large case-crossover study using an online gout survey (n = 633), cherry intake over a 2-day period was associated with a 35% lower risk of gout attack/flare, and any cherry extract use lowered the risk by 45%. 16 In combination with allopurinol, cherry intake was associated with a 75% risk reduction in gout flares. Cherry effects were independent of sex and race, as well as purine intake and alcohol consumption, which are risk factors for gout flares. The antigout benefits of cherries peaked around three servings over a 2-day period. 16 In one research report, a series of three small studies evaluated the use of cherry juice concentrate for gout flare prophylaxis. 25 The first study was a small randomized controlled trial (RCT) 
Urate-lowering potential of cherries and anthocyanins
The recognition of cherries as beneficial in gout management dates back to 1950. An article reported the lowering of SU to baseline with resolution of recurrent gout flares after consuming 0.5 lb of cherries daily in 12 patients with gout. 76 Unfortunately, there is a paucity of data examining the urate-lowering potential of cherries and cherry products. In an animal model evaluating the effects of tart cherry juice in normal and hyperuricemic rats, 14 days of treatment with tart cherry juice (5 ml/kg) significantly decreased (20%) SU in hyperuricemic rats, a finding not seen in normal controls. Hepatic XO was inhibited by 20% in hyperuricemic rats, suggesting a potential, though limited role in lowering SU through XO inhibition. In comparison, allopurinol 5 mg/kg showed 58% XO inhibition. 77 Significant urate-lowering effects were also seen in two studies using healthy human participants, with a notable difference between the two cherry products used. The plasma urate concentration decreased by 14% 5 h after consuming two servings of sweet Bing cherries (~45 cherries), with a 73% increase in urinary urate at 3 h. 78 This compares with 30 ml (1 oz) of tart cherry concentrate (equivalent to 90 cherries), which was associated with ~36% decrease in SU, and ~250% increase in urinary urate excretion, 26 with similar results seen with 60 ml tart cherry concentrate. In contrast, two small studies using cherry juice concentrate for gout flare prophylaxis in patients with crystal-proven gout, also at a dose equivalent to ~90 cherries, showed a decrease in gout flare rate despite no significant change in SU from baseline. 25 These studies had small sample sizes, with the major difference between these studies being: (a) healthy subjects as compared with those with crystal-proven gout; (b) duration of treatment (hours versus months); and (c) the time of assessment, with the latter study measuring SU at day 0 and 120. These studies suggest that cherries may have urate-lowering properties, possibly through inhibition of XO or increased renal clearance, which were noted in healthy participants, but not in people with gout. However, the conflicting data, potential for publication bias (namely, negative studies less likely to be published), and lack of consensus as to which active compound in cherries lowers urate reiterates the need for future studies. Details of the studies examining the urate-lowering potential of cherries are shown in Table 4 .
Three small studies using anthocyanin extract (proposed active ingredient in cherries and cherry extracts) in animal models showed positive results suggesting anthocyanins may be beneficial in managing gout (Table 2) . A study examining the effects of a single dose of 100-300 mg/kg anthocyanin extracts from purple sweet potato on hyperuricemic mice 79 and rats 81 found that compared with hyperuricemic controls, SU decreased by 29-60%, 79,81 as compared with 5-10 mg/kg of allopurinol, which resulted in 82% reduction to undetectable SU levels. 79, 81 Anthocyanin extract was also found to inhibit XO up to 91% when compared with hyperuricemic controls in a dosedependent manner both in vivo and in vitro. 81 Extract from Hibiscus anthocyanins reduced SU by 70%. 80 These studies were limited, since none of them used anthocyanins extracted from cherries, raising the question of whether these properties are truly generalizable to the family of anthocyanins, regardless of the fruit of origin. Thus anthocyanins, an active ingredient in cherries, may have urate-lowering properties.
Gout treatment guidelines: how do they define the role of cherries in gout management? According to the 2012 American College of Rheumatology (ACR) guidelines for management of gout, an acute gouty arthritis attack should be treated with pharmacologic therapy, for which the three preferred options are NSAIDs, systemic corticosteroids, or oral colchicine. 82 Pharmacologic prophylaxis against flares is recommended when initiating or titrating ULT, preferably with colchicine or NSAIDs, should be initiated for the greater of: 6 months' duration, 3 months after achieving target SU in people without tophi, or 6 months after achieving target SU with resolution of prior tophi. 83 Cherry juice or extract was voted as inappropriate for the treatment of an acute gout attack. 82 Recommendations to avoid naturally sweet fruit juice were also included. 83 However, the guideline noted '…more research is needed in diet and lifestyle modifications for gout, especially direct intervention studies.' 83 The common occurrence of comorbidities in gout, including chronic kidney disease (CKD) and diabetes, as well as the CYP3A4 medication interactions, make it difficult to provide safe anti-inflammatory options for patients with active gout. NSAIDs inhibit prostaglandin synthesis through COX inhibition, 84 whereas colchicine exerts its beneficial effects via inhibition of microtubule polymerization and the NLRP3 inflammasome that contributes to the disruption of chemokine and cytokine secretion, as well as neutrophil migration. 85 The use of cherries was associated with a reduction of gout flares 16, 25 and inhibition of inflammatory processes related to the inhibition of pro-inflammatory cytokines 19, 25, 29, 44, 45, 53 or COX enzymes 20, 30, 31 in a manner similar to that of the current standard of care. Whether cherry extract or products can play an adjunctive role to ULT in the long-term management of gout needs to be examined using rigorous RCT, placebo-controlled designs. The ACR also recommends that patients with an established diagnosis of gout should be treated with chronic ULT if there is evidence of tophi, frequent attacks (at least two attacks per year), CKD II or worse, or history of urolithiasis. 83 Treatment should be initiated with the use of an XO inhibitor such as allopurinol or febuxostat as first-line therapy. Unfortunately, medication side effects, including the rare possibility of life-threatening hypersensitivity reactions with allopurinol and the recent data showing that febuxostat was associated with higher cardiovascular mortality and overall mortality, 86 have heightened the concern with the use of these ULTs. Cherries and their associated compounds may have inhibitory effects, often in a dose-dependent manner, on XO, 20, 77, 79, 81, 74 and therefore could be used as 12 journals.sagepub.com/home/tab complementary treatments, in addition to the use of traditional ULT.
Knowledge gaps: cherries and gout
There is a paucity of data to currently support the use of cherries or cherry products in the treatment of gout. Numerous questions remain regarding the use of cherries and the role they could conceivably play in the management of gout (Table 5 ).
For instance, at what dose would cherries and their contents be comparable with the currently available XO inhibitors? In a study using hyperuricemic mice, anthocyanin extract at a dose of 100 mg/kg inhibited XO by 62% compared with 80% inhibition with 10 mg/kg of allopurinol. 79 An in vitro study found that 10 mg/ml of anthocyanin extract inhibited XO activity by nearly 90%, as compared with allopurinol 100 mg that caused 60% inhibition in XO activity. 79 Another important question arises as to whether or not cherries may also have complementary effects when used in combination with allopurinol, an outcome seen in a study evaluating cherry consumption on recurrent gout attacks that noted a 75% risk reduction in gout attacks when combined with allopurinol. 16 Similarly, a study using cherry juice concentrate for gout flare prophylaxis observed that 62% of patients on ULT were flare free at 4-6 months when combined with cherry juice concentrate, as compared with only 36% of patients not on ULT that were flare free. 25 
Summary and conclusions
Despite the availability of effective ULT and antiinflammatory drugs for the treatment of gout, there is considerable interest in novel treatments and approaches to the management of gout. In a patientcentered approach, given the common use of cherries and related products by patients with gout, we provide a focused review examining the current evidence. Data indicate that cherries and their products have antioxidant properties, the capacity to inhibit several processes involved in the acute inflammatory response to the urate crystals, and the ability to decrease bone resorption that is characteristic of gouty bone erosions. Phenolics, and more specifically, the anthocyanins found abundantly in cherries, have been linked to the inhibition of IL-6, TNF-α, IL-1β, IL-8, COX-I and COX-II, as well as the downregulation of NFkB-mediated osteoclastogenesis, suggesting that cherries may have the ability to reduce both acute and chronic inflammation that play a role in recurrent gout flares and chronic destructive arthropathy. Additionally, cyanidin-3-glucoside enhanced genes related to osteoblast differentiation, suggesting that anthocyanins may also play a role in bone formation. The flavonol quercetin has also emerged as yet another beneficial component found in cherries, not only in its capacity as an antioxidant, but also through inhibition of XO and inflammatory cytokines. Though there is evidence that cherries may lower SU and inhibit XO, possibly mediated by anthocyanins or quercetin, the data comparing cherries with traditional ULT are lacking, and it is likely through inhibition of acute and chronic inflammation that cherries may have a future as a nonpharmacologic option in the management of gout. There are data, however, suggesting that cherries may have complementary effects on SU when combined with allopurinol, indicating yet another area in need of further examination. Is there a dose at which cherries or cherry products have a detrimental effect?
Which gout subpopulation can best benefit from the use of cherries, or cherry products?
At what dose are cherries, cherry products, or their contents comparable to allopurinol and febuxostat?
NSAIDs, nonsteroidal anti-inflammatory drugs.
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Given the potential beneficial effects of cherries, this powerful fruit is becoming a more attractive option, and clearly has a role in the management of gout. Unfortunately, there are no large RCTs on the use of cherries in the treatment of gout. It would seem that this is long overdue and may provide additional evidence as to the role cherries could play in the future management of a burdensome disease. Additionally, a number of questions still remain when it comes to using cherries in the management of gout, and the answers to these questions may provide substantial insight into the future role cherries may best fit into. Based on the data presented here and new data generated with rigorous RCTs and other translational studies, one potential future option might be to manage gout using ULT with 'a cherry on the top.'
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